Sees 2026 EPS hit of 14 cents from planned Apogee deal Quarterly revenue rose above forecasts to $16.99 billion Humira sales dropped 36% to $756 million, still tops estimate Skyrizi and Rinvoq beat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results